Seeking Alpha

ChinaMart » Comments » SSRX

  • China Biotech Week in Review: Earnings, Deals and Drug Development [View article]
    LTUS (Lotus Pharmaceuticals) reaffirmed 2008 guidance on Friday. That guidance of $13.8M USD in net income is about .29/share fully diluted...making the PE for LTUS well under 4.
    As far as I can tell, this makes LTUS the best value in the China Biopharma sector today.
    Jun 02 07:14 am |Rating: 0 0 |Link to Comment
More on SSRX by ChinaMart
Comments by Ticker
ChinaMart's
Comments Stats
30 comments
Rating: 0 (0 - 0 )